| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Molecular Biology, Pathobiology, and Genetics |
4 Integrin Transcription by Homeodomain-Interacting Protein Kinase 2 and p53 Impairs Tumor Progression
1Molecular Oncogenesis Laboratory, Department of Experimental Oncology, and 2Department of Pathology, Regina Elena Cancer Institute, Rome, Italy; 3Department of Oncology and Neurosciences, University of Chieti, Chieti, Italy; and 4Department of Internal Medicine, University of Turin, Turin, Italy
* To whom correspondence should be addressed. E-mail: falcioni{at}ifo.it.
| Abstract |
|---|
Increased expression of
6
4 integrin in several epithelial cancers promotes tumor progression; however, the mechanism underlying its transcriptional regulation remains unclear. Here, we show that depletion of homeodomain-interacting protein kinase 2 (HIPK2) activates
4 transcription that results in a strong increase of
4-dependent mitogen-activated protein kinase and Akt phosphorylation, anchorage-independent growth, and invasion. In contrast, stabilization of HIPK2 represses
4 expression in wild-type p53 (wtp53)-expressing cells but not in p53-null cells or cells expressing mutant p53, indicating that HIPK2 requires a wtp53 to inhibit
4 transcription. Consistent with our in vitro findings, a strong correlation between
4 overexpression and HIPK2 inactivation by cytoplasmic relocalization was observed in wtp53-expressing human breast carcinomas. Under loss of function of HIPK2 or p53, the p53 family members TAp63 and TAp73 strongly activate
4 transcription. These data, by revealing that
4 expression is transcriptionally repressed in tumors by HIPK2 and p53 to impair
4-dependent tumor progression, suggest that loss of p53 function favors the formation of coactivator complex with the TA members of the p53 family to allow
4 transcription. [Cancer Res 2009;69(14):5978–86]
Key Words:
integrin
6
4, HIPK2, p53 family members, transcription, tumor progression
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |